Go Back
UroGen Pharma Ltd. reports $30.2 million Q1 loss
By USInMinutes - May 11, 2023, 04:38 PM ET
Last Updated - Jul 18, 2023, 03:30 PM EDT
The company generated $17.20 million in quarterly revenue
UroGen Pharma Ltd. [URGN] has reported fiscal Q1 loss of $30.20 million.
On a per-share basis, the L3 based company said its diluted earnings are $1.30.
The Pharmaceutical Preparations firm posted revenue of $17.20 million in this period.
Also Read:
- UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments
- UroGen Pharma to Present at H.C. Wainwright BioConnect Conference
- UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments
- Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer
- UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer
NewsInMinutes is an offering of 10kInfo, Inc., bringing you news on the latest regulatory filings. You may subscribe to news alerts here.
Sponsored
Sponsored
Read More from Investing
Popular News
Latest News